Jounce Therapeutics: An Undervalued Biotech Flush With Big Pharma Cash

About: Jounce Therapeutics, Inc. (JNCE), Includes: BMY, CELG, FTSV, GILD, SURF
by: Adam May
This article is exclusive for subscribers.
Adam May
Long/Short Equity

Jounce therapeutics is a differentiated player in the hot immuno-oncology sector.

JNCE stock has not been fairly priced after its newly struck partnership with Gilead Sciences, making it a compelling buy for the short term.

JNCE's drug discovery engine continues to impress, potentially making it an equally compelling pick for the longer term.

Jounce Therapeutics (JNCE) is a small biotechnology company focused on the rapidly expanding industry of immuno-oncology. Armed with a productive drug discovery platform, a unique mid-stage lead candidate in lung cancer, and a